Share on StockTwits
 

Shire PLC (LON: SHP) received a number of ratings updates from brokerages and research firms in the last week:

  • Shire PLC had its “outperform” rating reaffirmed by analysts at BNP Paribas. They now have a GBX 3,100 ($50.86) price target on the stock.
  • Shire PLC had its “neutral” rating reaffirmed by analysts at Credit Suisse. They now have a GBX 3,200 ($52.50) price target on the stock.
  • Shire PLC had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a GBX 3,370 ($55.29) price target on the stock.
  • Shire PLC had its “buy” rating reaffirmed by analysts at Deutsche Bank. They now have a GBX 2,850 ($46.76) price target on the stock, down previously from GBX 3,850 ($63.17).
  • Shire PLC had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a GBX 3,400 ($55.78) price target on the stock.
  • Shire PLC had its “buy” rating reaffirmed by analysts at Societe Generale. They now have a GBX 3,615 ($59.31) price target on the stock.
  • Shire PLC had its “neutral” rating reaffirmed by analysts at UBS AG. They now have a GBX 3,180 ($52.17) price target on the stock.
  • Shire PLC had its price target raised by analysts at Citigroup Inc. from GBX 3,200 ($52.50) to GBX 3,600 ($59.06). They now have a “buy” rating on the stock.

Shares of Shire PLC (LON:SHP) opened at 3135.00 on Thursday. Shire PLC has a 52 week low of GBX 1853.0001 and a 52 week high of GBX 3169.00. The stock has a 50-day moving average of GBX 2956.42 and a 200-day moving average of GBX 2673.. The company’s market cap is £17.192 billion.

Shire plc (LON:SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.